Company Analysis
Sign in

Valneva SE (VALN)

Nasdaq: VALN · Biological Products, (No Diagnostic Substances) · Saint-Herblain, FR · filing with the SEC since 2021
Full chart Alerts Compare
Grade4.6
◀ Past 6.2● Present 4.3▶ Future 3.4
2 est.
OverviewBusinessFinancialsGradeForecastSentimentOwnershipPeopleFilingsPatents Chart
The companyfiscal 2025, as filed
Revenue€175M+3.0%
Net income-€115M-840.6%
Earnings per share€-0.68-750.0%
Operating cash flow-€52.9M+21.3%
Cash€110M-34.8%
Debt€179M-4.4%
Shareholders’ equity€106M-41.4%
Shares, diluted168.2M+15.4%
Return on equity-108.5%
The recordfrom its filings
Filings in 202631
Newest filingNov 6 · 6-K
Annual reportMar 17, 2026
Quarterly reportn/a
Next report due20-F by Apr 30
Insider sales, 12 months$0.00
Insider buys, 12 months$0.00
Patents granted68
Filer categoryAccelerated filer
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
Revenue and net income by fiscal yearRevenueNet income
19202122232425
As filed, in EUR. Nothing here is a forecast.

News

Jun 16, 2026 · SEC EDGAR · Form EFFECT
Registration effective
Open the filing on sec.gov
Jun 16, 2026 · SEC EDGAR · Form 424B3
Shelf offering
Open the filing on sec.gov
Jun 12, 2026 · SEC EDGAR · Form CORRESP
Reply to the SEC
Open the filing on sec.gov
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.
SI Assistanton VALN · research, not advice